Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C.V. Chae, P.M. Ridker, J.E. Manson.
Postmenopausal hormone replacement therapy and cardiovascular disease.
Thromb Haemost, 78 (1997), pp. 770-780
[2.]
M.H. Davidson, K.C. Maki, P. Marx, A.C. Maki, M.S. Cyrowski, N. Manavatin, et al.
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
Arch Intern Med, 160 (2000), pp. 3315-3325
[3.]
The Writing group for the PEPI trial. Effects of estrogen or estrogen/ progestin regimens on hearth disease risk factors in postmenopausal women.
JAMA, 273 (1995), pp. 199-200
[4.]
T.W. Meade.
Hormone replacement therapy and haemostatic function.
Thromb Haemostas, 78 (1997), pp. 765-769
[5.]
A.A. Nabulsi, A.R. Folsom, A. White, W. Patsch, G. Heiss, K.K. Wu, et al.
Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women.
N Engl J Med, 328 (1993), pp. 1069-1075
[6.]
J. Gilabert, A. Estellés.
El sistema fibrinolítico en la anticoncepción oral y en la terapéutica hormonal sustitutiva. Revisión y puesta al día.
Prog Obst Ginecol, 37 (1994), pp. 137-146
[7.]
J. Gilabert, A. Estellés, A. Cano, F. España, R. Barrachina, S. Grancha, et al.
The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status.
Am J Obstet Gynecol, 173 (1995), pp. 1849-1854
[8.]
A. Estellés, A. Cano, C. Falcó, F. España, J. Gilabert, J. Aznar.
Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause. Influence of hormone replacement therapy.
Thromb Haemost, 81 (1999), pp. 104-110
[9.]
G.Y. Lip, A.D. Blann, A.F. Jones, D.G. Beevers.
Effects of hormone-replacement therapy on hemostatic factors, lipids factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis.
Am Heart J, 134 (1997), pp. 764-771
[10.]
S. Venkavaara, A. Silveira, T. Hakala-Ala-Pietilä.
Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflamation and serum lipids and lipoproteins in postmenopausal women.
Thromb Haemost, 85 (2001), pp. 619-625
[11.]
F. Grodstein, J.E. Manson, G.A. Colditz, W.C. Willett, F.E. Speizer, M.J. Stampfer.
Postmenopausal hormone reduces risk of heart disease in healthy women.
Ann Intern Med, 133 (2000), pp. 933-941
[12.]
M. Cushman, C. Legault, E. Barrett-Connor, M.L. Stefanick, C. Kessler, H.L. Judd, et al.
Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study.
Circulation, 100 (1999), pp. 717-722
[13.]
E. Hoibraaten, E. Qvigstad, T.O. Andersen, M.C. Mowinckel, P.M. Sandset.
The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-results from a randomized, double-blind, clinical trial.
Thromb Haemost, 85 (2001), pp. 775-781
[14.]
G. Lowe, M. Woodward, M. Vessey, A. Rumley, P. Gough, E. Daly.
Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationship to hormone replacement therapy.
Thromb Haemost, 83 (2000), pp. 530-535
[15.]
S. Pérez-Gutthann, L.A. García-Rodríguez, J. Castellsague, A. Duque-Oliart.
Hormone replacement therapy and risk of thromboembolism: population based case-control study.
BMJ, 314 (1997), pp. 796-800
[16.]
C. Varas-Lorenzo, L.A. García-Rodríguez, C. Cattaruzzi, M.G. Troncon, L. Agostinis, S. Perez-Gutthann.
Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in Southern Europe.
Am J Epidemiol, 147 (1998), pp. 387-390
[17.]
E. Daly, M.P. Vessey, M.M. Hawkins, J.L. Carson, P. Gough, S. Marsh.
Risk of venous thromboembolism in users of hormone replacement therapy.
Lancet, 348 (1996), pp. 977-980
[18.]
M.A. Espeland, S.M. Marcovina, V. Miller, P.D. Wood, C. Wasilauskas, R. Sherwin, et al.
Effects of postmenopausal hormone therapy on lipoprotein(a) concentration.
Circulation, 98 (1998), pp. 979-986
[19.]
J.D. Douketis, M. Gordon, M. Johnston, J.A. Julian, J.R. Adachi, J.S. Ginsberg.
The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature.
Thromb Res, 99 (2000), pp. 25-34
[20.]
H.J. Teede, B.P. McGrath, J.J. Smolich, E. Malan, D. Kotsopoulos, Y.L. Liang, et al.
Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 1404-1409
[21.]
W.M. Van Baal, J.J. Emeis, M.J. van der Mooren, H. Kessel, P. Kenemans, C.D. Stehouwer, et al.
Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.
Thromb Haemost, 83 (2000), pp. 29-34
[22.]
U.H. Winkler, R. Altkemper, B. Kwee, F.A. Helmond, H.J. Coelingh Bennink.
Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study.
Fertil Steril, 74 (2000), pp. 10-19
[23.]
O.E.C. Gebara, M.A. Mittleman, B.W. Walsh, I. Lipinska, F.K. Welty, G. Bellogi, et al.
Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia.
Heart, 80 (1998), pp. 235-239
[24.]
K.K. Koh, M.K. Horne, R. Cannon.
Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women.
Thromb Haemostas, 82 (1999), pp. 626-633
[25.]
P.Y. Scarabin, M. Alhencgelas, G. Plubureau, P. Traisne, R. Agher, M. Aiach.
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 3071-3078
[26.]
C. Falcó, G. Tormo, A. Estellés, F. España, E. Tormo, J. Gilabert, et al.
Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy.
Haematologica, 86 (2001), pp. 92-98
[27.]
S. Grancha, A. Estellés, G. Tormo, C. Falcó, J. Gilabert, F. España, et al.
Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Influence of hormone replacement therapy.
Thromb Haemost, 81 (1999), pp. 516-521
[28.]
S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, E. Riggs, et al.
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
JAMA, 280 (1998), pp. 605-613
[29.]
E. Sbarouni, Z. Kyriakides, D. Kremastinos.
The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease.
J Am Coll Cardiol, 32 (1998), pp. 1244-1250
Copyright © 2001. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.